Convergent Akt activation drives acquired EGFR inhibitor resistance in lung cancer

Non-small-cell lung cancer patients with activating epidermal growth factor receptor (EGFR) mutations typically benefit from EGFR tyrosine kinase inhibitor treatment. However, virtually all patients succumb to acquired EGFR tyrosine kinase inhibitor resistance that occurs via diverse mechanisms. Th...

Descripción completa

Detalles Bibliográficos
Autores principales: Jacobsen, Kirstine, Bertran-Alamillo, Jordi, Molina, Miguel Angel, Teixidó, Cristina, Karachaliou, Niki, Pedersen, Martin Haar, Castellví, Josep, Garzón, Mónica, Codony-Servat, Carles, Codony-Servat, Jordi, Giménez-Capitán, Ana, Drozdowskyj, Ana, Viteri, Santiago, Larsen, Martin R., Lassen, Ulrik, Felip, Enriqueta, Bivona, Trever G., Ditzel, Henrik J., Rosell, Rafael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583255/
https://www.ncbi.nlm.nih.gov/pubmed/28871105
http://dx.doi.org/10.1038/s41467-017-00450-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583255/
https://www.ncbi.nlm.nih.gov/pubmed/28871105
http://dx.doi.org/10.1038/s41467-017-00450-6

Ejemplares similares